艾昆纬：2026年欧洲生物类似药可持续发展记分卡：总体概况及各国评分（英文版）（62页）.pdf

1、MAY2026Overall Summary and Country ScorecardsBiosimilar Sustainability Scorecards for Europe 2026IntroductionBiosimilar Sustainability Scorecards for Europe 2026:Overall Summary and Country ScorecardsAs biosimilars continue to play an expanding role in European healthcare systems,it is increasingly

2、important to understand not only the savings and access gains they generate,but also the market conditions required to maintain those benefits over time.IQVIA Institute published scorecards on the sustainability of biosimilar markets in 2018.This report aims to review this sustainability and how hea

3、lth care systems have evolved over time highlighting the positive levers and areas of development for biosimilar healthcare systems.This report highlights the value of biosimilars and evaluates the structural determinants of biosimilar market sustainability(i.e.long term viability of competition and

4、 supply)across a diverse set of European countries through a standardized,multi-dimensional assessment framework.It examines sixteen metrics across eight categories including pricing rules and dynamics,incentives,purchasing mechanisms,clinical guidelines and prescribing practices,competitive dynamic

5、s,and healthcare system performance to identify the policy configurations that support or hinder long-term biosimilar viability.By comparing country scorecards and underlying policy features,the analysis highlights where pricing compression,procurement rigidity,or weak incentive alignment may underm

6、ine manufacturer participation,as well as where balanced frameworks can sustain competition and access.The aim of the report is to inform stakeholders who are involved in the delivery and provision of to biosimilars such as policymakers,payers,healthcare professionals to industry stakeholders by ill